Literature DB >> 21484732

Accumulation of renin and imidazolone in peritubular capillary endothelial cells in insulin-resistant hypertensive rats.

Zoltán Wagner1, Péter Degrell, Balázs Lukáts, Toshimitsu Niwa, Gergo A Molnár, Lajos Markó, Zoltán Karádi, István Wittmann.   

Abstract

BACKGROUND: Peritubular endothelium plays a key role in the development and progression of diabetic and nondiabetic chronic kidney disease. Renal injury in disorders of glucose metabolism may appear as early as in the stage of impaired glucose tolerance (IGT) and is accelerated by hypertension. The aim of our study was to investigate renal histology in rats with hypertension and IGT, with special emphasis on the peritubular endothelium.
METHODS: Hypertension and IGT (H/IGT) were provoked in adult male Wistar rats by bilateral administration of methylglyoxal into the ventromedial hypothalamus. Immunohistochemistry with anti-renin and anti-imidazolone antibodies and immunoelectron microscopy with anti-renin antibody were performed.
RESULTS: H/IGT rats showed tubulointerstitial fibrosis as well as renin and imidazolone staining in the papillary region. The patterns of immunostaining for renin and imidazolone were similar to that of endothelium. On electron microscopy, peritubular capillary endothelial cells and to a less extent, tubular epithelial cells showed renin positivity. DISCUSSION: Impaired glucose tolerance complicated with hypertension leads to tubulointerstitial fibrosis in rat kidney. Imidazolone deposition and renin production in peritubular capillary endothelial cells may play a role in the development of tubulointerstitial fibrosis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21484732     DOI: 10.5301/JN.2011.6520

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  1 in total

Review 1.  Methylglyoxal, obesity, and diabetes.

Authors:  Paulo Matafome; Cristina Sena; Raquel Seiça
Journal:  Endocrine       Date:  2012-09-16       Impact factor: 3.633

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.